Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2018

  • ID: 4516004
  • Report
  • 99 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Agenus Inc
  • Apogenix AG
  • BioNTech AG
  • Eli Lilly and Co
  • KAHR medical Ltd
  • MacroGenics Inc
  • MORE
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2018

Summary:

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). CD137 are involved in the regulation of a wide range of immune activities.

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 28 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 17 and 4 respectively. Similarly, the universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Metastatic Cancer, Metastatic Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Thyroid Cancer, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Esophageal Cancer, Gliosarcoma, Lung Cancer, Lymphoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Nasopharyngeal Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Primary CNS Lymphoma, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Sarcomas, Small-Cell Lung Cancer and Thymoma (Thymic Epithelial Tumor).

The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Agenus Inc
  • Apogenix AG
  • BioNTech AG
  • Eli Lilly and Co
  • KAHR medical Ltd
  • MacroGenics Inc
  • MORE
Introduction

Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development

Agenus Inc

Alligator Bioscience AB

Apogenix AG

Bicycle Therapeutics Ltd

BioInvent International AB

BioNTech AG

Bristol-Myers Squibb Co

Eli Lilly and Co

Juno Therapeutics Inc

KAHR medical Ltd

LeadArtis SL

MacroGenics Inc

Molecular Partners AG

Pfizer Inc

Pieris Pharmaceuticals Inc

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles

ABP-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aptamer to Antagonize CD137 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATOR-1016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATOR-1017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Agonize CD40 and 4-1BB for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target EphA2 and CD137 for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD137L for Nasopharyngeal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EU-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize CD137 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISAS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAHR-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAHR-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lisocabtagene maraleucel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize 41BB for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target HER2 and CD137 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize TNFRSF9 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD137 and IL2R for Metastatic Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-0310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-343 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCB-333 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize CD137 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ultra-41BBL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

urelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

utomilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Product Development Milestones

Featured News & Press Releases

Dec 12, 2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Dec 09, 2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL

Nov 09, 2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology

Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference

Oct 24, 2017: Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-

Oct 24, 2017: Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 - a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics

Oct 12, 2017: Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development

Oct 02, 2017: Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-

Aug 17, 2017: Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-

Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma

Jun 12, 2017: Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development

Jun 05, 2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma

May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting

May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Agenus Inc, H1 2018

Pipeline by Alligator Bioscience AB, H1 2018

Pipeline by Apogenix AG, H1 2018

Pipeline by Bicycle Therapeutics Ltd, H1 2018

Pipeline by BioInvent International AB, H1 2018

Pipeline by BioNTech AG, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Juno Therapeutics Inc, H1 2018

Pipeline by KAHR medical Ltd, H1 2018

Pipeline by LeadArtis SL, H1 2018

Pipeline by MacroGenics Inc, H1 2018

Pipeline by Molecular Partners AG, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Pieris Pharmaceuticals Inc, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Agenus Inc
  • Alligator Bioscience AB
  • Apogenix AG
  • Bicycle Therapeutics Ltd
  • BioInvent International AB
  • BioNTech AG
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Juno Therapeutics Inc
  • KAHR medical Ltd
  • LeadArtis SL
  • MacroGenics Inc
  • Molecular Partners AG
  • Pfizer Inc
  • Pieris Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll